Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters StreetEvents
$75.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

GI Dynamics Inc announces new EndoBarrier data from research with GlaxoSmithKline


Monday, 5 May 2014 06:00pm EDT 

GI Dynamics Inc:Announced that new data from a study with GlaxoSmithKline on EndoBarrier and its potential mechanism of action were presented at Digestive Disease Week 2014.During an oral presentation titled, “Duodenal-jejunal Bypass Liner Increases Fasting and Postprandial Serum Levels of Bile Acids in Patients with Severe Obesity.The increased level of bile acids we observed suggest that there may be a similar mechanism of action associated with EndoBarrier in the treatment of obesity and diabetes to that observed with gastric bypass.This mechanism may be the driver of the weight loss and glucose stabilization seen in patients treated with EndoBarrier.Researchers have proposed that increased postoperative levels of bile acids (BAs) may be tied to the effectiveness of a common type of gastric bypass surgery, Roux-en-Y gastric bypass. 

Company Quote

0.3
 --
21 Nov 2014